AI Article Synopsis
- Arsenic trioxide (As(2)O(3)) shows promise in treating acute promyelocytic leukemia and has been studied for its effects on human liver cancer cell lines, specifically SK-Hep-1, HepG2, and HuH7.
- In HuH7 cells, As(2)O(3) significantly decreased cell proliferation in a dose-dependent manner, while SK-Hep-1 and HepG2 cells were inhibited at higher concentrations.
- The study found that the effectiveness of As(2)O(3) is linked to the levels of intracellular glutathione (GSH), suggesting that lowering GSH could enhance the drug's sensitivity, indicating its potential as a treatment for hepatocellular carcinoma
Article Abstract
Arsenic trioxide (As(2)O(3)) has been shown to be effective for treatment of patients with refractory or relapsed acute promyelocytic leukemia and a variety of other malignant hematopoetic disorders. We studied the effect of this agent on proliferation of human hepatoma-derived cell lines (SK-Hep-1, HepG2, and HuH7). In HuH7 cells, As(2)O(3) reduced proliferation time- and dose-dependently at 1 and 2 microM, while in SK-Hep-1 and HepG2 cells, As(2)O(3) inhibited proliferation at 2 and 4 microM respectively. Cell cycle analysis by flow cytometry showed that As(2)O(3) induced apoptosis in these hepatoma-derived cells as confirmed by appearance of sub-G(1) cells. Sensitivity of hepatoma-derived cells to As(2)O(3) was inversely related to their intracellular glutathione (GSH) and intensity of GSH synthesis. Arsenic sensitivity was restored to relatively resistant cell lines when GSH was depleted by L-buthionine sulfoximine (BSO). These results indicate that As(2)O(3) may have therapeutic potential for treatment of hepatocellular carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0304-3835(01)00800-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ovarian clear cell carcinoma (OCCC), particularly advanced or recurrent settings, is generally resistant to platinum-based chemotherapy, warranting novel therapeutic strategies. Mutations in the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin kinase (PI3K/AKT/mTOR) pathway are frequently reported in OCCC. Therefore, we hypothesized that the PI3K/mTOR dual inhibitor, GSK458, and arsenic trioxide may exert synergistic anti-tumor effects on OCCC.
View Article and Find Full Text PDFHarnessing Arsenic Derivatives and Natural Agents for Enhanced Glioblastoma Therapy.
Cells
December 2024
Laboratory of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan.
Glioblastoma (GBM) is the most common and lethal intracranial tumor in adults. Despite advances in the understanding of the molecular events responsible for disease development and progression, survival rates and mortality statistics for GBM patients have been virtually unchanged for decades and chemotherapeutic drugs used to treat GBM are limited. Arsenic derivatives, known as highly effective anticancer agents for leukemia therapy, has been demonstrated to exhibit cytocidal effects toward GBM cells by inducing cell death, cell cycle arrest, inhibition of migration/invasion, and angiogenesis.
View Article and Find Full Text PDFSecond trimester medical abortion in acute promyelocytic leukaemia.
BMJ Case Rep
December 2024
Haematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Acute promyelocytic leukaemia (APL) is a highly lethal haematological malignancy. It is rare in pregnancy and may be fatal if not managed promptly and appropriately. A woman in her 20s presented with high-grade fever at 16 weeks of her third pregnancy.
View Article and Find Full Text PDFThe mechanism of arsenic trioxide and microwave ablation in the treatment of oral squamous cell carcinoma based on high throughput sequencing.
IET Syst Biol
December 2024
Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Oral squamous cell carcinoma (OSCC) is a common head and neck malignant tumour with high incidence and poor prognosis. Arsenic trioxide (ATO) has therapeutic effects on solid tumours. Microwave ablation (MWA) has unique advantages in the treatment of solid tumours.
View Article and Find Full Text PDFInduction treatments with and without addition of one dose anthracycline to all-trans retinoid acid and arsenic in pediatric non-high-risk acute promyelocytic leukemia: study protocol for a randomized controlled trial.
Trials
December 2024
Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Article Synopsis
- Acute promyelocytic leukemia (APL) treatment has improved significantly with all-trans retinoic acid (ATRA) and arsenic, but issues like coagulation disorders and differentiation syndrome still pose risks, especially in children.
- A multicenter randomized trial compares the effectiveness of ATRA plus chemotherapy (experimental group) against ATRA alone (control group) in treating pediatric patients with APL, focusing on reducing hyperleukocytosis and complications.
- The goal is to determine whether adding chemotherapy during treatment induction is beneficial in lowering mortality rates among non-high-risk pediatric APL patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!